Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig + Docetaxel in Advanced/Metastatic NSCLC
NCT06841055Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Mar 2025
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of pumitamig in non-small cell lung cancer (NSCLC) (3 arms), sponsored by BioNTech SE. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 90 days and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06841055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841055.